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Abstract
Background: To gain more insight into genetic causes of cerebral visual impairment (CVI) in children and to
compare ophthalmological findings between genetic and acquired forms of CVI.
Methods: The clinical data of 309 individuals (mainly children) with CVI, and a visual acuity ≤0.3 were analyzed for
etiology and ocular variables. A differentiation was made between acquired and genetic causes. However, in persons
with West syndrome or hydrocephalus, it might be impossible to unravel whether CVI is caused by the seizure disorder
or increased intracranial pressure or by the underlying disorder (that in itself can be acquired or genetic). In two
subgroups, individuals with ‘purely’ acquired CVI and with ‘purely’ genetic CVI, the ocular variables (such as strabismus,
pale optic disc and visual field defects) were compared.
Results: It was possible to identify a putative cause for CVI in 60% (184/309) of the cohort. In the remaining 40% the
etiology could not be determined. A ‘purely’ acquired cause was identified in 80 of the patients (26%). West syndrome
and/or hydrocephalus was identified in 21 patients (7%), and in 17 patients (6%) both an acquired cause and West
and/or hydrocephalus was present. In 66 patients (21%) a genetic diagnosis was obtained, of which 38 (12%) had other
possible risk factor (acquired, preterm birth, West syndrome or hydrocephalus), making differentiation between
acquired and genetic not possible. In the remaining 28 patients (9%) a ‘purely’ genetic cause was identified.
CVI was identified for the first time in several genetic syndromes, such as ATR-X, Mowat-Wilson, and Pitt Hopkins syndrome. In
the subgroup with ‘purely’ acquired causes (N= 80) strabismus (88% versus 64%), pale optic discs (65% versus 27%) and visual
field defects (72% versus 30%) could be observed more frequent than in the subgroup with ‘purely’ genetic disorders (N= 28).
Conclusions:We conclude that CVI can be part of a genetic syndrome and that abnormal ocular findings are present more
frequently in acquired forms of CVI.
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Background
Cerebral visual impairment (CVI) is one of the major
causes of low vision in the developed world and accounts
for 27% of the visually impaired children [1]. Visual im-
pairment in CVI is due to a disorder in projection and/or
interpretation of the visual input in the brain [2]. In the
absence of absolute criteria for the diagnosis, the following
definition is commonly used: CVI includes all visual
dysfunctions caused by damage to, or malfunctioning
of, the retrochiasmatic pathways in the absence of any
major ocular disease [3]. A more practical definition
includes an impairment of vision with normal function
of the ocular structures and anterior visual pathways
[4-6]. The main features of CVI during ophthalmological
investigation are: impaired visual acuity, visual field de-
fects, and abnormal visual behavior, while obvious ocular
abnormalities are not found. This visual behavior consists
of looking away from the target while reaching to it,
looking past the target, staring into lights, and fluctuat-
ing visual performances. Fixation abnormalities can be
observed, such as a prolonged time before fixating on a
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stimulus and intermittent fixation towards a stimulus [7,8].
The visual acuity can range from blindness to normal, and
is in CVI due to perinatal causes correlated to the severity
of the brain damage [9-11]. Crowding, the impairment of
the ability to recognize objects in clutter, is present in more
than 40% of the normally sighted CVI individuals, however,
in individuals with CVI and low vision the percentage
of crowding is unknown [10,12,13]. The occurrence of
strabismus (37-73%) and nystagmus (12-73%) varies
highly among previous reports [3,5,6]. In funduscopy a
(segmental) pale optic disc can be seen (25-44%), whereas
in premature born individuals a small optic disc or a more
pronounced excavation can be found [14]. Remarkably,
the latter could also be observed in individuals with muta-
tions in NR2F1, which were recently identified [15]. Visual
fields can be impaired, varying from partial visual field
defects, to severe constriction of visual fields [16]. It has
been demonstrated that visual evoked responses do not
differ between individuals with and without CVI, although
the responses can be abnormal [17]. In addition, fixation
is often severely impaired in CVI and minimal fixation is
necessary for visual evoked responses. Therefore, visual
evoked responses cannot be used to diagnose CVI. Fur-
thermore, difficulties with object or face recognition and
visiospatial disorders can be observed [7,18]. Neuro-
psychological testing can be helpful to gain more insight
in specific higher perceptual deficits in the individual, but
are only applicable to children with a developmental age
above two years and 9 months [19]. For a first screening
of higher perceptual functions several questionnaires have
been developed [10,20].
In general, the causes of CVI can be divided into
acquired and genetic forms. The acquired forms can be
derived prenatally (e.g. intrauterine infections), peri-
natally (e.g. ischemic brain injury), and postnatally (e.g.
hypoglycemia or meningitis). Perinatal problems, often
due to premature birth, are the most frequent causes of
acquired CVI, occurring in up to two-thirds of the cases,
whereas neonatal meningitis and/or encephalitis has
been reported as important causes in the postnatal period
(2.5-12%) [2,3,5,6,14]. Other acquired causes of CVI, such
as head trauma and brain tumors are less common [3,4,6].
In complex cases, like children with severe epilepsy or
hydrocephalus, it might be impossible to unravel whether
CVI is caused by the seizure disorder or increased intra-
cranial pressure or by the underlying disorder (that in
itself can be acquired or genetic) [21,22]. CVI, either ac-
quired or genetic, is often part of a more complex pheno-
type, and co-occurrence of non-ophthalmic impairments
and disorders, such as intellectual disability or epilepsy,
are common [3,6].
Knowledge about the occurrence of CVI in persons
with or without intellectual disability can alter the way
of approaching the person. For example, it is important
to offer objects one by one or for a longer period of time,
in case of crowding or fixation abnormalities. Moreover,
rehabilitation of children with CVI can improve their
overall function [23].
Although few studies reported on large series of 100
to 170 individuals with CVI, little attention is paid to
whether genetic disorders are involved [3,5,6]. Several
studies have been performed on higher perceptual deficits
in more common genetic syndromes, such as Williams
syndrome and Prader-Willi syndrome [24,25]. However,
in the description of these patients in those reports a re-
duced visual acuity is not mentioned. Our goal was to
get more insight into the genetic causes of CVI with low
vision. Because in acquired forms of CVI the mechanism
and the moment of disruption are different compared to
CVI due to genetic causes, we also aimed to investigate
whether different ocular phenotypes could be observed
for genetic versus acquired forms.
Methods
All individuals with CVI included in this study were seen
in Bartiméus, an institute for diagnostics, rehabilitation
and schooling of the visually impaired in the Netherlands,
in the period 2002–2012. Assuming that the incidence
of visual impairment in 3.1 million Dutch children aged
0–15 years is similar to the 8 ⁄ 100 000 per year reported
in Scandinavia, approximately half of the annually recorded
children with low vision in the Netherlands are seen at
Bartiméus [1]. All children were referred to Bartiméus by
medical specialists, i.e. paediatricians, rehabilitation physi-
cians, ophthalmologists, general physicians and orthoptists.
The children were referred for different reasons, mostly
because of suspected visual impairment. A minority was
referred for further diagnosis such as electrophysiology.
The majority of children lived at home with their parents
and were seen in the outpatient facilities of the Institute.
All investigations were performed by a pediatric ophthal-
mologist with assistance of a technical ophthalmological
assistant and/or orthoptist. Visual acuity was measured
mono- and binocularly with correction of the refraction
error under controlled light conditions. Monocular vision
was measured by covering one eye by a special device for
occlusion which could be added to the glasses worn by
the patient. Visual acuity in young children or in individ-
uals with a young developmental age was measured by
forced preferential looking (Teller Acuity Cards, 55 cm),
or with “LH Symbols” (3 m) [26]. The confrontational
method with white Stycar balls, 5 cm, was used to estimate
the visual fields. The balls on a stick were presented in all
quadrants by a person behind the individual investigated. A
person in front looked for response to the presented object:
eye movements, pointing or a verbal response. Eye
alignment, fixation, following, and visual behavior were
observed. A handheld slit lamp was used to assess the
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anterior segment. In mydriasis, funduscopy and retinos-
copy were performed, whenever the patient and parents
agreed. But in case of lack of cooperation funduscopy and
retinoscopy were not always possible. Electroretinography
was rarely performed, because of developmental age or
behavioral problems. CVI was diagnosed when there was
no other ocular diagnosis which could explain the visual
impairment or visual field defect, and/or typical features
such as poor fixation or crowding, and/or CVI were found
at neuropsychological investigation. Neuropsychological
investigation of the visual functions was, however, not
possible in a majority of the individuals, because of their
developmental age. Although, there are tests available
from 2+9 years onwards, the tests used in Bartiméus in the
past 10 years were only applicable in patients with a devel-
opmental age above six years. Crowding was measured
with the C-test at 5 m or with a LH Symbols version of
the C-test on 40 cm as described in Huurneman et al.
and was defined increased when the crowded ratio was ≥2
[13,27,28]. Additional inclusion criteria were a first visit
over a 10 years period between 1-1-2002 and 1-1-2012
and low vision, defined as a visual acuity of ≤0.3 or <1.6 cy-
cles/cm at 55 cm or a visual field radius of ≤30° degrees
[1]. Under the age of three the visual acuity was measured
by Teller Acuity Cards and defined as decreased, when
the acuity in cycles/degree was below the normal range
for their age reported by Courage and Adams [29]. Exclu-
sion criterion was a second ocular diagnosis causing low
vision, such as cataract or retinopathy of prematurity.
Optic nerve atrophy was not an exclusion criteria, because
it can occur as a result of retrograde transsynaptic degen-
eration in CVI [30]. Primary (hereditary) optic atrophy or
congenital idiopathic nystagmus were excluded based on
the history and results during ocular examination by the
ophthalmologist. Bilateral amblyopia was excluded as re-
fraction was measured and corrected if necessary.
The most recent ophthalmologic examination was used
for further analyses, including binocular visual acuity,
visual fields, strabismus, nystagmus, refraction error
and the aspect of the optic disc. The use of vigabatrin
was registered because of the risk of constriction of
visual field [31]. To identify potential causes of CVI we
evaluated the genetic investigations, risk factors during
pregnancy, birth, and neonatal/childhood period, and
reports on cerebral imaging.
For the comparison of the ophthalmological findings
the data of the individuals with acquired causes and with
a genetic diagnosis were used. To avoid confounding
factors, which may contribute to CVI, additional cri-
teria were used to select the subgroups for this compari-
son. Individuals with West syndrome and hydrocephalus
as well as individuals with a genetic diagnosis in combin-
ation with a gestational age <37 weeks, unknown gesta-
tional age or acquired causes (e.g. perinatal problems)
were excluded. For the statistical analysis the Mann–
Whitney U test and the Fisher’s Exact test were used. A
p-value below 0.05 was considered to be significant. To
control for the false discovery rate at 0.05 we used the
Benjamini-Hochberg method [32]. This study was ap-
proved by the Ethics Committee of the Radboud university
medical center (Commissie Mensgebonden Onderzoek,
regio Arnhem-Nijmegen). According to the Committee in-
formed consent was not necessary, because all data were
processed anonymously. Local approval of the institute was
obtained. The study was conducted according to the tenets
of the Declaration of Helsinki.
Results
309 individuals with low vision fulfilled the criteria for
CVI. The general information about the cohort is pre-
sented in Table 1 and in more detail in Additional file 1:
Table S1. Almost half of the patients (151/309) had their
first ophthalmological examination before the age of three
years, whereas five individuals were over 18 years of age.
152 persons had more than one examination, and there
was a median interval of 28 months between the first and
the most recent examination. The persons without a
second examination (n = 157) had a median age of
46 months (5 months − 45 years). In 20% (62/309) of
the cohort there was a vision below 0.05 or 1.6 cycles/cm
at 55 cm (Teller acuity cards) (Table 2). High refraction
errors, myopia < −4 or hypermetropia > +4, were present
in 25% (42/172) of the persons. In 77% (226/295) a stra-
bismus and in 42% (113/270) a nystagmus was present.
Visual field defects were found in 60% (149/249), consist-
ing of constricted visual fields in half of the individuals.
(Partial) pale optic discs were present in 44% (128/293).
Fixation problems were present in 45% and fluctuating
visual performances 31%.
Co-morbidities were found in a high percentage, such
as intellectual disability (96%, 298/309, IQ < 70 or devel-
opmental delay) and hearing impairment (12%, 24/196,
hearing threshold above 25 dB) (ICD-10, http://www.who.
int/classifications/icd/en/) (Table 1). In 32% (71/221) the
gestational age was below 37 weeks, of which two-thirds
were born before 35 weeks. In 67% of the cohort a MRI-
scan was performed, which was reported normal in only
14% (28/206). Brain anomalies were either caused by a dis-
turbance in the developmental process (e.g. lissencephaly,
cortical dysplasia) and white matter disease (e.g. hypomye-
linisation) or acquired (e.g. periventricular leucomalacia
(PVL), stroke). We subdivided the patients in a normal
MRI group and an abnormal MRI group and searched for
the difference in ophthalmologic features. In the patients
with an abnormal MRI scan more pale optic disc were seen
(49% versus 14%, p = 0.001) (Additional file 2: Table S2).
It was possible to identify one or more possible causes
for CVI in 60% of the cohort. In 23% there was evidence
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of severe perinatal problems, such as hemorrhage or
infarctions, PVL or post-partum reanimation. In 11%
exogenous factors led to brain damage and CVI, such as
meningitis or encephalitis, a diabetic coma, or a compli-
cation during an operation. Hydrocephalus was present
in 6% and West syndrome in 9% of the cohort.
A genetic diagnosis was reported in 21% (Table 3), of
which 50% had a proven chromosomal aberration. In half
of the persons with a genetic syndrome other factors, such
as West syndrome or stroke, may have contributed to the
CVI. In the other half the CVI might be associated with
the genetic syndrome.
After excluding individuals who had multiple factors
that could have contributed to CVI a subgroup (N = 108)
remained, which allowed for the comparison of the ocular
findings between individuals with a ‘purely’ acquired form
of CVI (N = 80) and those with a ‘purely’ genetic form
(N = 28). There were no significant differences between
the groups according to the age at the ophthalmological
examination (72 months versus 54 months, p = 0.333) or
the use of vigabatrin (9% versus 7%, p = 1.00), of which a
known side effect is visual field constriction defects
(Table 4) [31]. The occurrence of blindness (16% versus
25%, p = 0.396), nystagmus (46% versus 35%, p = 0.357) or
high refraction errors (myopia: 4% versus 0%, p = 0.567;
hypermetropia; 6% versus 11%, p = 0.425) did not differ
significantly between the groups. In the ‘purely’ acquired
group, however, strabismus (88% versus 64%, p = 0.009),
visual field defects (72% versus 30%, p = 0.001) and
(partial) pale optic discs (65% versus 27%, p = 0.001)
were observed more often than in the ‘purely’ genetic
group. The type of visual field defects, concentric,
hemianopsy, or upper or lower visual field defects, did
not seem to differ between the two groups, but the
numbers were too small to make definite conclusions.
Discussion
We analyzed causes of CVI in a large cohort of 309 indi-
viduals with low vision in the Netherlands. Although
CVI has also been described in individuals with a (sub-)
normal visual acuity and higher perceptual deficits, within
this study only patients were selected with a vision ≤0.3 or
a visual field below 30 degrees [9,10,18]. For the purpose
Table 1 General information, co-morbidities, etiology of
the cohort
General information Median (range)
Age first examination (months) 36 (4 months- 45 years)
Age most recent examination (months) 53 (5 months – 45 years)
Birth weight (gram) 2980 (760–4750)
Gestational age (weeks) 39 (27–42)
Regarding N/Available
N (%)
Men 170/309 (55%)
Mortality 15/309 (5%)
Twins 20/309 (6%)
Gestational age <37 weeks 71/222 (32%)
Vigabatrin use 44/309 (14%)
Anomalies MRI-cerebrum 178/206 (86%)
Co-morbidities Affected N/Available
N (%)
Intellectual disability 298/309 (96%)
Motor impairment 288/294 (98%)
Hearing impairment 24/196 (12%)
Etiology Number (%)
Perinatal problems* 70 (23%)
PVL* 35
Stroke* 32
Exogenic* 33 (11%)
Meningitis/encephalitis * 13
Congenital CMV infection* 6
Headtrauma* 6
Complication of operation/co-morbidity* 8
Genetic diagnosis* 66 (21%)
Hydrocephalus* 20 (6%)
West syndrome* 28 (9%)
Unknown 125 (40%)
*Can coexist.
Table 2 Findings of ophthalmological examinations
Ocular findings Affected N/Available
N (%)
Myopia < −4 13/171 (8%)
Hypermetropia > +4 29/171 (17%)
Visual acuity < 0.05 or <1.6 cycles/cm at 55 cm 62/309 (20%)
Strabismus 226/295 (77%)
Nystagmus 113/270 (42%)
Eye movement disorders 100/283 (35%)
Visual field defect 149/249 (60%)
Hemianopsia 28/149 (19%)
Upper or lower visual field defect 37/149 (25%)
Constriction of visual field 84/149 (56%)
(Partial) pale optic disc 128/293 (44%)
Visual behavior/higher visual disorders Percentage
Fluctuating visual performances 31%
Fixation abnormalities 45%
Looking away from the target 19%
Crowding 8%
Problems with object/face recognition 7%
Staring at lights 15%
Auditive stimuli dominates 9%
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of this study, we excluded persons with major anterior
ocular diseases, although CVI can also be present in those
patients. In some persons only grating acuity (Teller Acu-
ity Cards) could be measured. In general using grating
acuity initially may lead to higher scores than the optotype
acuity that can be applied later in development [55].
Although some children were investigated at a very young
age, which might hamper the differentiation between CVI
and delayed visual maturation (DVM), about half of the
individuals had more than one ophthalmological examin-
ation, with a median interval of 28 months between the
first and the most recent examination, whereas another
quart of the persons were over 48 months allowing for
an accurate clinical diagnosis. We hypothesized that in
Table 3 Syndromic diagnosis in patients with CVI
ID Diagnosis* GA Contributing
factors
Age at examination
(months)
CVI previously
reported
Evidence for
genetic diagnosis
Gene
269 Aicardi syndrome 36 W 50 [33] C
316 Aicardi syndrome 42 W 108 C
173 Aromatic decarboxylase deficiency 32 38 [34] C,M
319 ATR-X 38 70 C,G ATRX
55 CDG type 1a 41 22 [35,36] C,M
305 CDG type 1a NA 25 C,M
223 Citrullinaemia NA 81 C,M
128 Coffin-Siris syndrome 41 84 C
43 Cohen syndrome 38 53 C
433 Complex I deficiency NA 15 [37,38] C,M
378** Complex I deficiency 40 35 C,M
403 Complex II deficiency 41 46 [37] C,M
5 Complex III deficiency 41 W 73 C,M
266 Complex I and III deficiency NA 50 C,M
29 Complex II and III deficiency 42 S 48 C,M
175 D2-hydroxyglutaaraciduria NA 20 [39-41] C,M
425 Incontinentia Pigmenti 40 S, W 67 [42,43] C
184 Infantile neuroaxonal dystrophy 39 45 [44,45] C
325 Copper storage disorder 41 27 [46] C,M
263 Lissencephaly NA 38 [47] C,G DCX
231 Marden-Walker syndrome 35 79 C
17 Mowat-Wilson syndrome 41 34 C,G ZEB2
215 Opitz C syndrome NA 199 C
216 Pelizaeus-Merzbacher syndrome 38 27 [4] C,G PLP1
192 Pitt-Hopkins syndrome 40 35 C,G TCF4
85 Pontocerebellar hypoplasia type
2 Triple X
36 30 [48] C, C,G
238 Propion acidemia 36 117 [49] C,M
78 Rett syndrome 36 23 C,G MECP2
99 Rett syndrome 38 20 [50] C,G CDKL5
172 Rett syndrome NA 14 C,G CDKL5
364 Rett syndrome NA 197 [51,52] C
341 Tuberous sclerosis NA Compression from tubers 179 [4] C
41 Tuberous sclerosis NA Compression from tubers 165 C
348 Vanishing white matter NA 28 [53] C
*in an additional 33 individuals chromosomal aberrations were identified. **previously described in Morava et al. [54]. ATR-X syndrome = Alpha-Thalassemia
X-linked intellectual disability syndrome, CDG = congenital disorder of glycosylation, C = clinical diagnosis, GA = gestational age, G = gene mutation, M =metabolic
diagnosis, NA = not available, P = perinatal problems, S = stroke, W =West syndrome. The syndromes in the bold formatted rows are for the first time associated
with CVI.
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children with DVM there is a concordant delay in visual
functions. In CVI, on the contrary, there may be dis-
crepancies in the developmental stage of different visual
functions. When this hypothesis is correct, it might be
possible to differentiate earlier between CVI and DVM by
signaling discrepancies in the profile of visual functions.
This is a retrospective study based on the medical files
so that sometimes information is missing, for example
on ERG, ophthalmological results or MRI scan. In addition,
for some features (e.g. fixation) only abnormalities were
reported, although this was probably assessed in all pa-
tients but not always recorded. However, we were able to
collect a large group of patients and in the majority of
these patients extended investigations were performed.
The ocular findings in our cohort were comparable to
previous reports, except for the visual field defects, of
which a higher percentage was found in our study (60%
versus 9%) [3,6]. In two-thirds of the patients an MRI -
scan was performed. In only 14% of the individuals with
an MRI scan of the brain, the images were reported to
be normal (28/206), which is comparable with a previ-
ous study by Khetpal et al. [6]. The spectrum of MRI
abnormalities in our cohort was broad: from structural
abnormalities, such as corpus callosum dysplasia, holopro-
sencephaly or lissencephaly, to white matter abnormal-
ities, such as hypomyelinisation and PVL. This shows that
many different mechanism that lead to brain disease
may cause CVI. In individuals with a normal MRI scan
or only a thin corpus callosum, the pathogenesis was
less clear. Pale optic discs were seen more frequently
in the patients with reported anomalies on MRI scan.
However, as the MRI scans were assessed by many
radiologists with different expertise we are reluctant to
draw firm conclusions.
In 60% of the individuals, we were able to identify the
cause of the CVI, of which 32 persons were classified in
more than one group. In 34% evidence of acquired prob-
lems, mainly perinatal, were found which is lower than
the 42% - 67% previously reported [3,5,6]. This might be
due to more stringent criteria used in our study, as only
individuals with known brain damage on cerebral imaging,
twin-twin transfusion syndrome or postpartum resuscita-
tion were classified as perinatal problems.
In 40% of the patients we could not identify a cause
for CVI. This can be due to missing information in the
medical file, a not recognized acquired cause (for example
an unrecognized CMV infection during pregnancy), a not
identified genetic cause or a combination of several minor
acquired and genetic risk factors.
In 21% of the individuals a genetic diagnosis was ob-
tained, of which 50% had proven chromosomal aberra-
tions (Table 3). As the techniques to identify underlying
genetic causes are improving rapidly, this 21% is probably
an underestimation.
We observed various genetic syndromes for which an as-
sociation with CVI has previously been reported: trisomy
21, congenital disorder of glycosylation (CDG) type 1A,
complex II deficiency, copper storage diseases, infantile
neuroaxonal dystrophy, Pelizaeus-Merzbacher syndrome
and Rett syndrome [4,35-37,44-46,50-52,56-58]. However,
for the following genetic syndromes such association was
not reported so far: Alpha-Thalassemia X-linked intellectual
disability syndrome, Coffin-Siris syndrome, Pitt-Hopkins
syndrome, Mowat-Wilson syndrome and Cohen syndrome.
Table 4 Ocular findings in individuals with a ‘purely’ acquired or a ‘purely’ genetic cause
Acquired (N = 80) Genetic (N = 28) Raw p-value
Mean age most recent examination (months) 70 (SD 58) 54 (SD 39) 0.333
Affected N/Available N Affected N/Available N
Men 48/80 (60%) 17/28 (61%) 1.00
Vigabatrin use 7/80 (9%) 2/28 (7%) 1.00
Abnormal MRI 55/56 (98%) 11/14 (79%) 0.023
Myopia < −4 3/80 (4%) 0/28 (0%) 0.567
Hypermetropia > +4 5/80 (6%) 3/28 (11%) 0.425
Visual acuity <0.05 or <1.6 cycles/cm at 55 cm 13/80 (16%) 7/28 (25%) 0.396
Strabismus 68/77 (88%) 18/28 (64%) 0.009*
Nystagmus 31/67 (46%) 9/26 (35%) 0.357
Visual field defect 47/65 (72%) 7/23 (30%) 0.001*
Hemianopsia 10/47 1/7 -
Upper or lower visual field defect 19/47 3/7 -
Constriction of visual field 18/47 3/7 -
(Partial) pale optic disc 51/78 (65%) 7/26 (27%) 0.001*
*p-Values represent differences that passed the Benjamini–Hochberg criterion (false discovery rate at 0.05).
Bosch et al. BMC Ophthalmology 2014, 14:59 Page 6 of 9
http://www.biomedcentral.com/1471-2415/14/59
In some of these syndromes retinal diseases have been
described, for example in Cohen syndrome or CDG type
1A [35,59]. In our cohort an electroretinography was
often not available. However, as funduscopy did not re-
veal any retinal abnormalities, retinopathy was unlikely
to cause visual impairment. In neurodegenerative diseases,
such as complex II deficiency, optic atrophy can occur as
a result of mitochondrial dysfunction, but these disorders
affect the brain equally [37]. Moreover, retrograde transsy-
naptic atrophy may occur, making differentiation between
CVI and visual impairment due to optic atrophy in these
disorders difficult.
Although CVI might still be a coincidental finding in
the above mentioned genetic syndromes, most individuals
with these or other syndromes have not systematically
been tested for CVI. For example, visual acuity, visual
behavior, and the findings at funduscopy are seldom
reported in the clinical reports and children with an in-
tellectual disability are not always seen by a pediatric
ophthalmologist. Therefore, it is likely that CVI might
be a consistent part of these syndromes, but a thor-
ough assessment of the visual functions in more indi-
viduals with these syndromes is necessary to establish
this association.
We were able to establish a diagnosis in the majority
of CVI in our study population, consisting of genetic dis-
orders and acquired causes. After exclusion of possible
confounders a ‘purely’ genetic and a ‘purely’ acquired sub-
group remained. Between those two different etiologies
the ophthalmological examination revealed significant dif-
ferences (Table 4). Strabismus, visual field defects and
(partial) pale optic disc were significantly less common in
the genetic group compared to the acquired group. This
might be explained by the localization of the defect as in
the acquired group, the most important cerebral damage
was PVL and stroke, both mainly localized in the optic
radiations. Damage to the optic radiations can cause visual
field defects and retrograde optic disc pallor [14,30,60]. In
the genetic group the optic radiations are probably less
severely affected and a more overall dysfunction of the
brain and/or cortical anomalies might have resulted in the
visual impairment. This theory is supported by the ob-
servation that normal optic discs are seen more often
in individuals with cortical lesions compared to subcor-
tical lesions [60]. A comparable mechanism might result
in the higher frequency of strabismus in the acquired
group. To guide the alignment of the visual axes the bin-
ocular connections in the striate cortex play an important
role [61]. When the input to the striate cortex is disturbed
by prism-glasses, strabismus develops in primates [62].
So it can be expected that injury to the optic radiations
by stroke or PVL, which also disrupts the input to the
striate cortex, leads to strabismus. Although there are more
mechanisms that cause strabismus, the above mentioned
probably accounts for the difference between the two
groups.
Conclusions
In conclusion, we presented a large cohort of mainly chil-
dren with CVI and impaired vision. Genetic disorders
were present in 21% of patients and an association be-
tween the disorder and CVI is considered. CVI patients
with genetic disorders showed an overall different and
milder ocular phenotype: less frequently strabismus, visual
field defects and pale optic discs. Moreover, we observed
CVI for the first time in several known genetic syndromes
making the screening of visual functions in those syn-
dromes recommendable, to ensure the best approach and
clinical care to the often multiple disabled persons. Also
clinical genetic investigation should be considered in per-
sons with CVI without evidence of an acquired cause.
Awareness of CVI as part of a genetic disorder is currently
increasing, and the techniques to identify the underlying
genetic defect are improving rapidly. Therefore, it is likely
that more genetic defects will be identified to be associ-
ated with CVI in the near future.
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